

1. NAME OF THE MEDICINAL PRODUCT

AL-MAG^(R) Suspension

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each 5ml of suspension contains:

Magnesium Trisilicate	250mg
Light Magnesium Carbonate.....	250mg
Sodium Bicarbonate.....	250mg

Excipients with known effect:

For a full list of excipients, see section 6.1.

3. PHARMACEUTICAL FORM

- Oral Liquid/Suspension.
- A white viscous suspension

4. Clinical Particulars

4.1 Therapeutic indications

For relief of the symptoms of indigestion, heartburn and dyspepsia.

4.2 Posology and method of administration

- Posology
- Adults and children over 12 years: two to four 5ml spoonfuls.
- Children 5 to 12 years: one to two 5ml spoonfuls.
- Method of administration

Oral.

Directions for use: shake the bottle.

Take in a little water.

To be taken three times a day or as required.

4.3 Contraindications

Contraindicated in severe renal failure, hypophosphataemia and in patients who must control sodium intake e.g. congestive heart failure, hypertension, cirrhosis of the liver. Should not be administered to patients with metabolic or respiratory alkalosis, hypocalcaemia or hypochlorhydria. Hypersensitivity to any of the ingredients.

4.4 Special warnings and precaution for use

The product should be used with caution in patients with fluid retention. In view of the sodium bicarbonate content, the product should also be administered extremely cautiously to patients with renal impairment, to patients receiving corticosteroids or patients with respiratory acidosis, eclampsia, or aldosteronism. If renal function is impaired hypermagnesaemia.

4.5 Interactions with other medicinal products and other forms of interaction

Antacids may interact with a number of other drugs by altering their absorption and, sometimes, their elimination, thereby reducing their effectiveness. Antacids may also damage enteric coatings designed to prevent dissolution in the stomach. In order to minimise the risk of interactions, this product should not be taken within two to four hours of other medications (allow at least 4 hours before or 2 hours after erlotinib).

Examples of other medications which may be affected include, but are not limited to ACE inhibitors, salicylates e.g. aspirin, atazanavir, azithromycin, barbiturates, bile acids, bisphosphonates, cephalosporin antibiotics, fluoroquinolone antibiotics, chloroquine and hydroxychloroquine, deflazacort, digoxin, dipyridamole, eltrombopag, erlotinib, fexofenadine, gabapentin, iron preparations, isoniazid, itraconazole, ketoconazole, lansoprazole, levothyroxine, lithium, methenamine, mycophenolate, nitrofurantoin, penicillamine, phenothiazines, phenytoin, proguanil, rifampicin, rosuvastatin, sulpiride, tetracyclines, tipranavir, ulipristal (avoid use with antacids).

There is a risk of metabolic alkalosis when oral magnesium salts are given with polystyrene sulphonate resins.

4.6 Pregnancy and Lactation

Animal studies are insufficient with respect to effects on pregnancy, embryonal/foetal development, parturition and postnatal development. The potential risk for humans is unknown. As there is no specific data for this product, it is recommended that AL-MAG suspension only be used in pregnancy on the advice of a doctor.

Caution should be exercised when prescribing to pregnant women as this product contains sodium.

4.7 Effects on ability to drive and use machines

- None.

4.8 Undesirable effects

Magnesium salts may cause diarrhoea in some patients. Magnesium carbonate and sodium bicarbonate may cause stomach cramps and flatulence as a result of excess carbon dioxide production.

Long-term, excessive use has been associated with the development of silica-based renal calculi.

4.9 Overdose

Overdose, or excessive or prolonged intake of magnesium containing antacids may give rise to hypermagnesaemia, and excessive administration of sodium hydrogen carbonate may lead to hypokalaemia and metabolic alkalosis, especially in patients with renal insufficiency.

Symptoms of hypermagnesaemia include nausea, vomiting, flushing of the skin, thirst, drowsiness, hypotension, confusion, muscle weakness, CNS and respiratory depression, hyporeflexia, peripheral vasodilatation, bradycardia, cardiac arrhythmias, coma and cardiac arrest.

Symptoms of hypokalaemia and metabolic alkalosis include mood changes, tiredness, shortness of breath, muscle weakness and irregular heart beat. Muscle hypertonicity, twitching and tetany may develop, especially in hypocalcaemic patients. Excessive doses of sodium salts may lead to sodium overloading and hyperosmolality.

Treatment of mild hypermagnesaemia is usually limited to restricting magnesium intake. In severe hypermagnesaemia, ventilatory and circulatory support may be required. Treatment should consist of the intravenous administration of calcium gluconate injection 10% at a dose of 10 – 20ml, to counteract respiratory depression or heart block. If renal function is normal, adequate fluids should be given to assist magnesium removal from the body. Haemodialysis may be necessary in patients with renal impairment or for whom other methods prove ineffective. Metabolic alkalosis and hypernatraemia can be treated by appropriate correction of fluid and electrolyte balance. Replacement of calcium, chloride, and potassium ions may be of particular importance.

5. Pharmacological properties:

5.1 Pharmacodynamic properties

- AL-MAG Suspension is an antacid with slow neutralising action and mild laxative action.

5.2 Pharmacokinetic properties

Magnesium chloride and hydrated silica gel are formed during the neutralisation. About 5% of magnesium is absorbed and traces of liberated silica may be absorbed and excreted in the urine.

Any sodium bicarbonate not neutralised in the stomach is absorbed and excreted as bicarbonate and sodium ions in the urine in the absence of a plasma deficit.

5.3 Preclinical safety data

- None Known.

6. Pharmaceutical particulars

6.1 List of excipients

- Citric Acid
- Xanthan Gum
- Peppermint Oil
- Chloroform
- Disodium Edetate
- Purified Water

6.2 Incompactibilities

- Not Applicable.

6.3 Shelf life

36 Months

6.4 Special precautions for storage

- Store in a cool dry place protected from light and out of reach of children.

6.5 Nature and contents of container<and special equipment for use, administration or implantation>

Flint pet bottles of 100ml and 200ml.

6.6 Special precautions for disposal<and other handling>

- None.

7. Applicant/Manufacturer

- Name: Alben Healthcare Industries Limited.
- Address: Km 15 Old Onitsha-Awka Road Ogidi, Anambra State, Nigeria.
- Phone No: 08068056661.
- Email Address:albenng@rocketmail.com.